Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Egetis Therapeutics AB (publ) (EGTX.ST)
SEK6.28
+0.05 (+0.80%)
SE STO Healthcare Biotechnology
Address
Klara Norra Kyrkogata 26 111 22
Stockholm, SE
Stockholm, SE
CEO
Nicklas Westerholm
Website
egetis.com
IPO
2011-04-07
ISIN SE0003815604
Description
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK6.28
+0.05 (+0.80%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
856.7K
Beta
0.79
Float Shares
219.23M
Free Float %
55.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.74% | +2.62% | +10.98% | +32.34% | +7.93% | +29.01% | +73.70% | -13.94% | +14.60% | -84.04% | -51.02% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
6.28
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-2.66
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+35.4% ★ Q1'26: +5.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+17.0% Q1'26: -33.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-550.6% Q1'26: -479.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-555.9% Q1'26: -677.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-174.0% Q1'26: -200.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+20.1% Q1'26: +9.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.22× Q1'26: -0.21× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 2 EPS Ana. |
Dec 2027 4 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13.59M
est: 8.30M (+63.7%)
|
28.21M
est: 75.00M (-62.4%)
|
82.56M
est: 60.89M (+35.6%)
|
40.66M
est: 39.76M (+2.3%)
|
38.24M
est: 41.50M (-7.8%)
|
22.50M
est: 28.54M (-21.2%)
|
57.60M
est: 70.80M (-18.6%)
|
46.10M
est: 54.19M (-14.9%)
|
62.40M
est: 66.83M (-6.6%)
|
657.64M
541.33M – 734.17M
+884.1% YoY
|
460.55M
178.21M – 646.34M
-30.0% YoY
|
1.17B
1.14B – 1.20B
+154.9% YoY
|
1.66B
1.36B – 1.85B
+41.2% YoY
|
2.27B
1.86B – 2.53B
+36.6% YoY
|
| EBITDA |
-87.94M
est: -8.30M (-959.5%)
|
—
est: -75.00M (+100.0%)
|
-61.21M
est: -60.89M (-0.5%)
|
-177.63M
est: -39.76M (-346.8%)
|
-101.90M
est: -41.50M (-145.5%)
|
-191.00M
est: -28.54M (-569.2%)
|
-319.10M
est: -70.80M (-350.7%)
|
-317.40M
est: -54.19M (-485.8%)
|
-346.90M
est: -66.83M (-419.1%)
|
-657.64M
-734.17M – -541.33M
-884.1% YoY
|
-460.55M
-646.34M – -178.21M
+30.0% YoY
|
-1.17B
-1.20B – -1.14B
-154.9% YoY
|
-1.66B
-1.85B – -1.36B
-41.2% YoY
|
-2.27B
-2.53B – -1.86B
-36.6% YoY
|
| EBIT |
-87.94M
est: -8.30M (-959.5%)
|
-85.00M
est: -75.00M (-13.3%)
|
-61.42M
est: -60.89M (-0.9%)
|
-178.02M
est: -39.76M (-347.8%)
|
-104.30M
est: -41.50M (-151.3%)
|
-193.70M
est: -28.54M (-578.7%)
|
-322.70M
est: -70.80M (-355.8%)
|
-317.30M
est: -54.19M (-485.6%)
|
-346.90M
est: -66.83M (-419.1%)
|
-657.64M
-734.17M – -541.33M
-884.1% YoY
|
-460.55M
-646.34M – -178.21M
+30.0% YoY
|
-1.17B
-1.20B – -1.14B
-154.9% YoY
|
-1.66B
-1.85B – -1.36B
-41.2% YoY
|
-2.27B
-2.53B – -1.86B
-36.6% YoY
|
| Net Income |
-87.94M
est: -397.60M (+77.9%)
|
-85.00M
est: -291.02M (+70.8%)
|
-61.43M
est: -453.97M (+86.5%)
|
-179.12M
est: -376.04M (+52.4%)
|
-104.73M
est: -171.57M (+39.0%)
|
-189.50M
est: -286.10M (+33.8%)
|
-326.90M
est: -402.41M (+18.8%)
|
-343.60M
est: -337.20M (-1.9%)
|
-342.50M
est: -296.45M (-15.5%)
|
319.30M
235.24M – 403.36M
+207.7% YoY
|
-33.80M
-36.93M – -30.67M
-110.6% YoY
|
347.00M
278.15M – 415.85M
+1,126.6% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
15.63M
est: 19.30M (-19.0%)
|
11.33M
est: 174.37M (-93.5%)
|
13.33M
est: 141.57M (-90.6%)
|
11.10M
est: 92.43M (-88.0%)
|
14.51M
est: 96.49M (-85.0%)
|
74.30M
est: 66.36M (+12.0%)
|
172.80M
est: 206.36M (-16.3%)
|
215.30M
est: 157.93M (+36.3%)
|
201.00M
est: 194.77M (+3.2%)
|
1.92B
1.58B – 2.14B
+884.1% YoY
|
1.34B
519.41M – 1.88B
-30.0% YoY
|
3.42B
3.34B – 3.51B
+154.9% YoY
|
4.83B
3.98B – 5.40B
+41.2% YoY
|
6.60B
5.43B – 7.37B
+36.6% YoY
|
| EPS |
-1.63
est: -1.30 (-25.7%)
|
-1.58
est: -0.95 (-66.4%)
|
-1.08
est: -1.48 (+27.1%)
|
-2.44
est: -1.23 (-98.9%)
|
-0.58
est: -0.56 (-3.6%)
|
-0.98
est: -0.88 (-11.0%)
|
-1.27
est: -1.14 (-11.6%)
|
-1.12
est: -0.89 (-25.4%)
|
-0.93
est: -0.84 (-11.0%)
|
0.87
0.64 – 1.10
+203.5% YoY
|
-0.09
-0.10 – -0.08
-110.6% YoY
|
0.98
0.76 – 1.13
+1,168.6% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-265.16M
OE per share TTM
-0.70
Owner's Yield
-9.99%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
8.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-91.3K
Shares Outstanding
395.16M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nicklas Westerholm | Chief Executive Officer | 7M | male |
| Ingemar Lundström | Founder | — | — |
| Karl Hard | Head of Investor Relations & Business Development | — | — |
| Katayoun Welin-Berger | Vice President of Operations | — | — |
| Laetitia Szaller | General Counsel & Head of Compliance and ESG | — | female |
| Louis Joseph Ignarro | Founder | — | — |
| Rob Towart | Founder | — | — |
| Torsten Almén | Founder | — | male |
| Associate Heidi Brurok | Founder | — | — |
| Yilmaz Mahshid | Chief Financial Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EGTX.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
